Takeda Pharmaceutical (NYSE:TAK) Upgraded to Strong-Buy at Zacks Research

Zacks Research upgraded shares of Takeda Pharmaceutical (NYSE:TAK) from a hold rating to a strong-buy rating in a research note issued to investors on Wednesday,Zacks reports.

Several other research analysts also recently weighed in on TAK. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Weiss Ratings cut Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

Takeda Pharmaceutical Price Performance

Takeda Pharmaceutical stock opened at $18.71 on Wednesday. Takeda Pharmaceutical has a 12-month low of $12.99 and a 12-month high of $18.90. The stock has a market capitalization of $59.95 billion, a P/E ratio of 55.03 and a beta of -0.07. The firm’s 50-day moving average is $17.26 and its two-hundred day moving average is $17.20. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.95 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.54. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The business had revenue of $7.50 billion during the quarter, compared to the consensus estimate of $7.13 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. Equities analysts predict that Takeda Pharmaceutical will post 1.54 earnings per share for the current year.

Insider Transactions at Takeda Pharmaceutical

In other Takeda Pharmaceutical news, insider Samaan Farajallah sold 14,006 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $17.10, for a total transaction of $239,502.60. Following the transaction, the insider owned 116,177 shares of the company’s stock, valued at $1,986,626.70. This trade represents a 10.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Andrew Plump sold 116,191 shares of Takeda Pharmaceutical stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $18.49, for a total transaction of $2,148,371.59. Following the completion of the transaction, the insider owned 145,465 shares in the company, valued at approximately $2,689,647.85. This trade represents a 44.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 592,922 shares of company stock valued at $10,340,896 in the last quarter. Insiders own 0.04% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Parkside Financial Bank & Trust boosted its holdings in Takeda Pharmaceutical by 192.2% in the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock valued at $40,000 after acquiring an additional 1,684 shares during the last quarter. SHP Wealth Management purchased a new position in shares of Takeda Pharmaceutical in the 4th quarter worth about $42,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Takeda Pharmaceutical by 313.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock worth $48,000 after purchasing an additional 2,328 shares during the period. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Takeda Pharmaceutical by 56.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after purchasing an additional 1,292 shares in the last quarter. Finally, Harbour Investments Inc. lifted its stake in shares of Takeda Pharmaceutical by 300.3% in the 4th quarter. Harbour Investments Inc. now owns 4,612 shares of the company’s stock valued at $72,000 after purchasing an additional 3,460 shares in the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.